Tracing the Heart: An Evidence-Linked Pipeline for Heart-Failure Feature Engineering

Introduction: The Clinical Imperative for Heart-Failure Feature Engineering

Heart failure is not a niche problem. It affects approximately 6.2 million adults in the United States alone, according to the American Heart Association's 2023 Statistical Update. Globally, that number exceeds 64 million. The condition carries a brutal prognosis—roughly 50% of patients die within five years of diagnosis, a mortality rate that rivals many cancers. The economic toll is equally staggering: over 1 million hospitalizations annually in the U.S., at a cost exceeding $30 billion, per the CDC.

These numbers matter for a simple reason: heart failure is a syndrome of repeated decompensation. Patients who are stable today can spiral into acute fluid overload tomorrow, ending up in the ICU. The clinical question driving much of modern heart failure research is deceptively simple—which patients are at risk, and when?

Machine learning offers a path toward answering that question at scale. But here's the uncomfortable truth: models are only as good as the data they're trained on, and raw clinical data is messy, sparse, and riddled with missingness. This is where feature engineering becomes not just helpful, but essential. Feature engineering is the process of transforming raw clinical measurements into the structured, informative inputs that machine learning models actually learn from.

This article walks through an evidence-linked pipeline for heart-failure feature engineering—a structured approach that grounds every step in clinical knowledge and validated research. The goal is practical: to give researchers and data scientists a clear, reproducible framework for turning raw clinical data into features that improve prediction, reduce noise, and—critically—produce models clinicians can trust.

Foundations: Understanding Heart Failure and Its Data Landscape

Clinical Definition and Phenotypes

Heart failure is a clinical syndrome in which the heart cannot pump enough blood to meet the body's metabolic demands. The symptoms—dyspnea, fatigue, fluid retention—are familiar to any clinician. But heart failure is not a single disease; it's a spectrum with distinct phenotypes defined by ejection fraction (EF), the percentage of blood the left ventricle pumps out with each contraction:

• HFrEF (Heart Failure with Reduced Ejection Fraction): EF ≤ 40%
• HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): EF 41–49%
• HFpEF (Heart Failure with Preserved Ejection Fraction): EF ≥ 50%

This distinction matters enormously for feature engineering. HFrEF and HFpEF have different underlying pathophysiology, different treatment protocols, and different risk trajectories. A feature set optimized for HFrEF may perform poorly on HFpEF patients—or worse, produce misleading predictions.

Key Clinical Variables

Certain variables appear with striking consistency across heart failure prediction models. A systematic review in Heart Failure Reviews (2021) found that age, sex, ejection fraction, and NT-proBNP appeared in over 70% of models reviewed. Other workhorse features include:

• NT-proBNP / BNP: Natriuretic peptides released by the heart under wall stress. The ESC guidelines flag NT-proBNP > 125 pg/mL as abnormal.
• Creatinine and BUN: Renal function proxies; cardiorenal syndrome is common in HF.
• Hemoglobin: Anemia is both a comorbidity and a predictor of worse outcomes.
• Ejection fraction: The central phenotypic variable.
• Comorbidities: Hypertension, diabetes, coronary artery disease, atrial fibrillation.
• Demographics: Age, sex, and increasingly, social determinants of health.

The Framingham Heart Study—which began in 1948—identified hypertension, coronary artery disease, and diabetes as major risk factors. Those same variables remain core features in modern ML models. Evidence doesn't expire.

The Role of EHRs and Public Datasets

Electronic Health Records (EHRs) provide longitudinal, structured data ideal for feature engineering: medication histories, repeated lab measurements, vital sign trajectories, and coded diagnoses. For researchers without direct hospital access, public datasets like MIMIC-III and MIMIC-IV (freely accessible critical care databases from Beth Israel Deaconess Medical Center) have become the de facto standard for HF research. These datasets contain rich ICU data—including lab values, vitals, and outcomes—that support both static and temporal feature extraction.

Key Takeaway: Heart failure is a heterogeneous syndrome. Feature engineering must account for phenotype differences (HFrEF vs. HFpEF) and lean on well-validated clinical variables like EF and NT-proBNP, which appear in the majority of successful prediction models.

Step 1: Data Acquisition and Preprocessing for HF Modeling

Sources of Data

The data landscape for heart failure research spans several sources:

• EHRs: Structured data (labs, vitals, diagnoses), unstructured notes, medication orders.
• Clinical registries: Disease-specific databases like the American Heart Association's Get With The Guidelines registry.
• Wearables: Continuous physiological data—heart rate, physical activity, weight, heart rate variability.

Each source has trade-offs. EHRs offer depth but suffer from missingness and documentation lag. Wearables provide longitudinal granularity but capture a healthier, more engaged population. Registries offer curated quality but limited breadth.

Handling Missing Data

Missing data is not an edge case in HF research—it's the norm. Patients skip lab draws, transfer between facilities, or die before follow-up. The strategies fall into three buckets:

1. Imputation: Mean/median imputation for simple cases; multiple imputation or MICE for more complex patterns.
2. Exclusion: Dropping patients or variables with excessive missingness. Simple, but risks selection bias.
3. Missingness indicators: Creating binary features that flag whether a value was missing. This is underappreciated—missingness itself can be clinically informative. A patient who never had a BNP drawn may differ systematically from one who did.

Data Cleaning and Normalization

Structured clinical data needs standard cleaning: converting units (creatinine in mg/dL vs. µmol/L), handling impossible values (negative BP, EF > 100%), and normalizing distributions. Many clinical variables are right-skewed (NT-proBNP is the classic example), so log transformation is often applied before use in linear models.

Step 2: Domain-Driven Feature Creation

Static Features: Demographics, Labs, Vitals

The foundation of any HF model is a set of static features captured at a single time point—typically admission or diagnosis:

• Age and sex: Non-negotiable. The Framingham risk score uses both.
• Vital signs: Systolic and diastolic BP, heart rate, respiratory rate, oxygen saturation.
• Lab values: Creatinine, BUN, hemoglobin, sodium, potassium, glucose.
• Ejection fraction: Most recent measurement before the prediction point.

Biomarkers and Their Thresholds

Clinical guidelines don't just provide variables—they provide thresholds. The ESC's 2021 guidelines designate NT-proBNP > 125 pg/mL as abnormal in the non-acute setting. These thresholds can be encoded directly as binary features, though continuous values often carry more information. A pragmatic approach: include both the continuous value and a threshold-based flag.

Comorbidity and Medication-Based Features

Comorbidities matter—not just as individual features, but as interaction terms. Diabetes plus chronic kidney disease carries a different risk profile than either alone. Guidelines from AHA and ESC enumerate conditions that modify HF management: hypertension, diabetes, atrial fibrillation, coronary artery disease, COPD, and chronic kidney disease.

Medication data is also valuable. A patient on a beta-blocker, ACE inhibitor, and SGLT2 inhibitor is receiving guideline-directed medical therapy. Whether they're adherent to that therapy—and whether their doses have been up-titrated—carries prognostic signal.

Key Takeaway: Domain knowledge isn't a constraint on feature engineering—it's the engine. Encoding guideline thresholds (like NT-proBNP > 125 pg/mL) and comorbidity patterns from AHA/ESC guidelines produces features that are both predictive and clinically interpretable.

Step 3: Temporal and Longitudinal Feature Engineering

Capturing Disease Progression

Static features capture a snapshot. But heart failure is a trajectory. A patient whose weight has increased 3 kg over five days is heading toward decompensation, even if today's weight is "normal." This is where temporal features earn their keep.

Common temporal features include:

• Slopes and trends: Linear regression slope of weight, BP, or creatinine over a window.
• Change scores: Value at admission minus value 24 hours prior.
• Volatility: Standard deviation of heart rate or blood pressure over time—a proxy for autonomic instability.
• Time since last event: Days since prior HF hospitalization.

Feature Extraction from Repeated Measurements

EHR data is irregularly spaced—labs are drawn at variable intervals, vitals are measured at different frequencies. This irregularity must be handled explicitly. Options include:

• Resampling to fixed intervals (e.g., hourly) and interpolating gaps.
• Windowing: Computing summary statistics (mean, min, max, slope) over clinically meaningful windows—e.g., 6, 12, or 24 hours.
• Sequence features: For deep learning, raw time-series segments can be fed directly into RNNs or transformers.

Case Study: Predicting Acute Decompensation

A study using MIMIC-III data engineered features such as mean arterial pressure, creatinine, and BUN trends over 24 hours to predict acute decompensated heart failure, achieving an AUC of 0.83. The static values alone performed substantially worse. The message: the change in a lab value often carries more signal than the value itself.

Step 4: Feature Selection and Dimensionality Reduction

Why More Features Aren't Always Better

High-dimensional feature sets (hundreds or thousands of features) can improve training performance but hurt generalization. Models overfit to noise, and the resulting predictions fail on new populations. The trade-off between model complexity and generalizability is central to HF modeling, where datasets are often modest in size.

Methods for Feature Selection

Three broad approaches dominate:

1. Filter methods: Univariate statistical tests (e.g., chi-square, mutual information) to rank features by predictive power.
2. Wrapper methods: Recursive feature elimination—train a model, drop the weakest features, repeat.
3. Embedded methods: LASSO regression (L1 penalty) and random forest importance scores select features during training.

LASSO is particularly popular in HF research because it produces sparse models—fewer features, easier interpretation. Random forest importance provides a complementary view, capturing non-linear relationships.

Balancing Interpretability and Performance

There's a tension between including every potentially informative feature and keeping models interpretable. Clinicians won't adopt a model that requires 500 inputs. A pragmatic approach: start with domain-driven features (Step 2), add temporal features (Step 3), then use LASSO or importance scores to prune to a parsimonious set—typically 10–30 features.

Key Takeaway: Feature selection is not a luxury—it's a necessity. LASSO and random forest importance provide principled ways to reduce dimensionality, but the final feature set should always be reviewed by clinicians for plausibility.

Step 5: Model Building and Validation with Engineered Features

Choosing Appropriate ML Models

The feature engineering pipeline feeds into any number of model architectures:

• Logistic regression: Baseline, highly interpretable, works well with sparse feature sets.
• Gradient boosting (XGBoost, LightGBM): Handles non-linearities and interactions; consistently strong in tabular clinical data.
• Random forests: Robust, good with mixed feature types.
• Deep learning: LSTM/transformer models for raw time-series; CNNs for ECG waveforms.

For most structured EHR data, gradient boosting is the pragmatic default. It captures non-linear relationships without the data hunger of deep learning.

Internal Validation

Cross-validation (especially k-fold, k=5 or 10) is standard. But clinical data introduces a complication: patients, not just rows, must be separated between training and test folds. Otherwise, the same patient's multiple admissions can leak information across folds, inflating performance estimates.

Calibration is equally important. A model can have high AUC but poorly calibrated probabilities—predicting 80% risk when the true rate is 60%. Platt scaling or isotonic regression should be applied, and calibration curves reported.

External Validation

The gold standard: test the model on a different population. A model trained on MIMIC-III (ICU patients) may fail when applied to outpatient EHR data. External validation across different hospitals, healthcare systems, or countries is the only way to assess true generalizability. Features that work in one population may not transfer—differences in demographics, data quality, and clinical practice all matter.

Interpretability and Clinical Adoption: Making Features Trustworthy

The Role of SHAP and LIME

Black-box models don't get adopted in medicine. Clinicians need to understand why a model flagged a patient as high-risk. SHAP (SHapley Additive exPlanations) values assign each feature a contribution score for a given prediction. LIME (Local Interpretable Model-agnostic Explanations) approximates the model locally with an interpretable surrogate.

These tools allow clinicians to see, for a specific patient, that elevated NT-proBNP, declining systolic BP, and a rising creatinine trend drove the risk prediction. That kind of transparency builds trust.

Aligning Engineered Features with Clinical Reasoning

The most interpretable models are those whose features align with clinical reasoning. A model that flags a patient because of rising creatinine and weight gain over 48 hours is explaining itself in terms clinicians already use. This alignment is a feature engineering goal, not an afterthought.

Key Takeaway: Interpretability is not optional for clinical adoption. SHAP and LIME make model decisions transparent, but the deeper win comes from engineering features that inherently reflect clinical logic.

Challenges and Ethical Considerations in HF Feature Engineering

Data Quality and Missingness Mechanisms

Missing data isn't random. Patients with severe HF get more labs drawn; healthier patients have sparser data. This informative missingness can bias models. Understanding why data is missing—clinical severity, access to care, documentation practices—is essential for choosing appropriate handling strategies.

Bias and Fairness Across Demographic Groups

Heart failure disproportionately affects Black and Hispanic populations in the U.S., yet many datasets underrepresent these groups. Models trained on homogeneous data can perpetuate or amplify disparities. Fairness auditing—measuring model performance across demographic subgroups—should be standard practice.

Privacy and Security

EHR data is among the most sensitive personal data. De-identification, secure data storage, and compliance with HIPAA (or GDPR for European data) are non-negotiable. Public datasets like MIMIC-IV have undergone rigorous de-identification, but researchers working with institutional data bear the responsibility for protecting patient privacy.

Future Directions: Deep Learning and Beyond

Automatic Feature Extraction from Raw Signals

Deep learning is increasingly capable of learning features directly from raw data. A deep learning model on ECG signals automatically extracted features like QRS duration and T-wave morphology to detect reduced ejection fraction, achieving an AUC of 0.91. Wearable sensor data—heart rate variability, physical activity patterns—can similarly feed end-to-end models, reducing the need for manual feature engineering.

This doesn't make manual feature engineering obsolete. Rather, it shifts the role: domain experts now curate the data types and model architectures rather than individual features.

Social Determinants of Health

Income, education, neighborhood, and access to care are associated with HF outcomes. A hospital readmission model that included social determinants like income and distance to clinic improved readmission prediction by 15% over baseline. These variables are increasingly available in EHRs or linkable via geocoding.

The Evolving Role of Feature Engineering in the Age of Foundation Models

Large language models and foundation models trained on massive clinical corpora may eventually generate features automatically. But these models are years away from reliable clinical deployment. For now, evidence-linked feature engineering remains the most robust path to accurate, interpretable, and trustworthy HF models.

Conclusion: Building a Robust Evidence-Linked Pipeline

The pipeline is straightforward in concept:

1. Acquire and preprocess data from EHRs, registries, or wearables.
2. Create domain-driven features from clinical guidelines and validated biomarkers.
3. Add temporal features to capture disease trajectory.
4. Select features using LASSO, importance scores, and clinical review.
5. Build and validate models with rigorous internal and external validation.
6. Interpret and audit for fairness and clinical alignment.

Each step is grounded in clinical evidence—from ESC thresholds to Framingham risk factors—and each step requires collaboration between data scientists and clinicians. The models that work aren't built by either group alone.

The stakes justify the effort. Heart failure kills hundreds of thousands of people each year, and machine learning offers a genuine opportunity to identify at-risk patients earlier, tailor treatments more precisely, and prevent decompensation events that lead to hospitalization and death. But that opportunity is only realized when data is transformed thoughtfully, rigorously, and with clinical wisdom at every step.

The features you engineer today are the predictions that save lives tomorrow.

Frequently Asked Questions

What is the purpose of feature engineering in heart failure prediction?

Feature engineering transforms raw clinical data—lab values, vitals, demographics—into structured inputs that machine learning models can use effectively. It improves prediction accuracy, reduces noise, and—critically—creates features that align with clinical reasoning, making models more interpretable and trustworthy.

Which clinical variables are most important for heart failure models?

Age, sex, ejection fraction, and NT-proBNP appear in over 70% of published HF prediction models. Other important variables include creatinine, BUN, hemoglobin, comorbidities (hypertension, diabetes, atrial fibrillation), and medication regimens.

How do you handle missing data in heart failure feature engineering?

Three strategies: imputation (mean/median/MICE), exclusion (dropping patients or variables with excessive missingness), and missingness indicators (binary flags indicating whether a value was absent). The latter is underused—missingness itself can be clinically informative.

What are temporal features and why are they useful?

Temporal features capture how variables change over time—slopes, trends, volatility, change scores. They matter because heart failure is a trajectory: a patient gaining 3 kg over five days is at risk of decompensation even if today's weight is "normal." Temporal features often outperform static values.

Can deep learning replace manual feature engineering for heart failure?

Partially. Deep learning can automatically extract features from raw signals like ECGs or wearable data, achieving strong performance (e.g., AUC 0.91 for detecting reduced EF). However, for structured EHR data, manual feature engineering remains more robust and interpretable, and it's better suited to modest dataset sizes.

What are the challenges in using EHR data for heart failure feature engineering?

Informative missingness (sicker patients have more data), irregular measurement intervals, documentation variability, and limited representation of certain demographic groups. These factors can bias models and require careful handling.

How do you validate heart failure prediction models?

Internal validation uses k-fold cross-validation with patient-level separation (not row-level) and calibration assessment. External validation tests the model on a different population, hospital, or dataset—essential for assessing true generalizability.

What is the role of interpretability in heart failure models?

Interpretability is essential for clinical adoption. SHAP and LIME explain individual predictions, but deeper interpretability comes from engineering features that reflect clinical logic—rising creatinine, weight gain, elevated NT-proBNP—so the model explains itself in terms clinicians already use.

Are there publicly available datasets for heart failure research?

Yes. MIMIC-III and MIMIC-IV are widely used public EHR databases with rich ICU data. The American Heart Association's Get With The Guidelines registry is another resource, though access may require application and approval.

What are the ethical considerations in using AI for heart failure?

Data privacy and security (HIPAA/GDPR compliance), bias and fairness across demographic groups (HF disproportionately affects Black and Hispanic populations), and the risk of models perpetuating healthcare disparities. Fairness auditing should be standard practice.

Ready to transform raw clinical data into life-saving insights? Explore our advanced feature engineering toolkit and join the community of researchers building the next generation of heart failure AI models.